← All trials
NCT06496971
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 1, 2024
- Primary completion
- Dec 31, 2026
- Completion date
- Mar 31, 2027
- First posted
- Jul 11, 2024
- Last posted
- Jul 12, 2024
- Enrollment
- 32
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- NaviFUS CorporationLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.